{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:52:00Z","timestamp":1773330720555,"version":"3.50.1"},"reference-count":240,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008979","name":"Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Endocrinologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005630","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005630","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ando.2025.102471","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T15:51:25Z","timestamp":1763653885000},"page":"102471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Society of Atherosclerosis (NSFA) and the French Society of Cardiology (SFC)"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-6714","authenticated-orcid":false,"given":"Benjamin","family":"Bouillet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Boulestreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"B\u00e9liard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Boccara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sybil","family":"Charri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene","family":"Valero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9753","key":"10.1016\/j.ando.2025.102471_bib0005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet Lond Engl"},{"issue":"25","key":"10.1016\/j.ando.2025.102471_bib0010","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ando.2025.102471_bib0020","first-page":"e563","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"34","key":"10.1016\/j.ando.2025.102471_bib0025","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"issue":"42","key":"10.1016\/j.ando.2025.102471_bib0030","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.ando.2025.102471_bib0035","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jacc.2017.08.006","article-title":"A test in context: lipid profile, fasting versus nonfasting","volume":"70","author":"Nordestgaard","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ando.2025.102471_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clinbiochem.2017.11.007","article-title":"Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital","volume":"52","author":"Cartier","year":"2018","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ando.2025.102471_bib0045","doi-asserted-by":"crossref","first-page":"117312","DOI":"10.1016\/j.atherosclerosis.2023.117312","article-title":"Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook","volume":"383","author":"Raja","year":"2023","journal-title":"Atherosclerosis"},{"issue":"39","key":"10.1016\/j.ando.2025.102471_bib0050","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Heart J"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0055","first-page":"101185","article-title":"Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: paper of the French Society of Cardiology and the French-speaking Society of Diabetology","volume":"47","author":"Valensi","year":"2021","journal-title":"Metabolism"},{"issue":"4S","key":"10.1016\/j.ando.2025.102471_bib0060","first-page":"S117","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0065","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/eurjpc\/zwad318","article-title":"Validation of Systematic Coronary Risk Evaluation 2 (SCORE2) and SCORE2-Older Persons in the EPIC-Norfolk prospective population cohort","volume":"31","author":"van Trier","year":"2024","journal-title":"J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/2047487320916589","article-title":"Imaging subclinical atherosclerosis in cardiovascular risk stratification","volume":"28","author":"Kozakova","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0075","first-page":"177","article-title":"Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review","volume":"98","author":"Peters","year":"2012","journal-title":"Br Card Soc"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0080","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1001\/jamacardio.2024.5644","article-title":"Coronary artery calcium testing\u2014Too early, late, often","volume":"10","author":"Zheutlin","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.ando.2025.102471_bib0085","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jcmg.2023.03.008","article-title":"When does a Calcium Score equate to secondary prevention?: Insights from the Multinational CONFIRM Registry","volume":"16","author":"Budoff","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib0090","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jcmg.2021.06.011","article-title":"The Added Value of Coronary Calcium Score in predicting cardiovascular events in familial hypercholesterolemia","volume":"14","author":"Gallo","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib0095","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamacardio.2017.4191","article-title":"Coronary artery Calcium Score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the Multi-Ethnic Study of Atherosclerosis","volume":"2","author":"Malik","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ando.2025.102471_bib0100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pcad.2023.03.002","article-title":"Coronary artery calcium, hepatic steatosis, and atherosclerotic cardiovascular disease risk in patients with type 2 diabetes mellitus: results from the Dallas heart study","volume":"78","author":"Khawaja","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"issue":"10","key":"10.1016\/j.ando.2025.102471_bib0105","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1805971","article-title":"Coronary CT angiography and 5-year risk of myocardial infarction","volume":"379","author":"Newby","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ando.2025.102471_bib0110","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jama.2012.9630","article-title":"Common carotid intima-media thickness measurements in cardiovascular risk prediction: meta-analysis","volume":"308","author":"Den Ruijter","year":"2012","journal-title":"JAMA"},{"issue":"1 Pt C","key":"10.1016\/j.ando.2025.102471_bib0115","doi-asserted-by":"crossref","first-page":"102147","DOI":"10.1016\/j.cpcardiol.2023.102147","article-title":"Usefulness of carotid ultrasound screening in primary cardiovascular prevention: a systematic review","volume":"49","author":"Sebastian","year":"2024","journal-title":"Probl Cardiol"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0120","doi-asserted-by":"crossref","first-page":"e005179","DOI":"10.1161\/JAHA.116.005179","article-title":"Comparison of Carotid Plaque Score and Coronary Artery Calcium Score for predicting cardiovascular disease events: the Multi-Ethnic Study of Atherosclerosis","volume":"6","author":"Gepner","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejvs.2019.07.039","article-title":"Three dimensional carotid and femoral ultrasound is not superior to two dimensional ultrasound as a predictor of coronary atherosclerosis among men with intermediate cardiovascular risk","volume":"59","author":"Jarauta","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/ATVBAHA.123.320138","article-title":"Assessment of subclinical atherosclerosis in asymptomatic people in vivo: measurements suitable for biomarker and Mendelian randomization studies","volume":"44","author":"Garg","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.ando.2025.102471_bib0135","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1177\/2047487319830485","article-title":"Cardiac calcification as a marker of subclinical atherosclerosis and predictor of cardiovascular events: review of the evidence","volume":"26","author":"Faggiano","year":"2019","journal-title":"J Prev Cardiol"},{"key":"10.1016\/j.ando.2025.102471_bib0140","first-page":"710","article-title":"LDL cholesterol in adults in metropolitan France: average concentration, awareness, and treatment in 2015, changes since 2006","volume":"37","author":"Lecoffre","year":"2018","journal-title":"Bull Epidemiol Hebd"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0145","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/ajcn\/77.5.1146","article-title":"Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials","volume":"77","author":"Mensink","year":"2003","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0150","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3945\/ajcn.2009.27661","article-title":"Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review","volume":"91","author":"Hunter","year":"2010","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"10.1016\/j.ando.2025.102471_bib0155","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11883-023-01109-y","article-title":"Eggs and cardiovascular disease risk: an update of recent evidence","volume":"25","author":"Carter","year":"2023","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"10.1016\/j.ando.2025.102471_bib0160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/obr.12433","article-title":"Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis","volume":"17","author":"Zomer","year":"2016","journal-title":"Obes Rev"},{"issue":"25","key":"10.1016\/j.ando.2025.102471_bib0165","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib0170","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/s41430-019-0504-z","article-title":"Phytosterol compositions of enriched products influence their cholesterol-lowering efficacy: a meta-analysis of randomized controlled trials","volume":"73","author":"Ying","year":"2019","journal-title":"Eur J Clin Nutr"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ptr.8052","article-title":"The effect of phytosterol supplementation on lipid profile: a critical umbrella review of interventional meta-analyses","volume":"38","author":"Wang","year":"2024","journal-title":"Phytother Res"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41467-021-27706-6","article-title":"Genome-wide meta-analysis of phytosterols reveals five novel loci and a detrimental effect on coronary atherosclerosis","volume":"13","author":"Scholz","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ando.2025.102471_bib0185","unstructured":"Phytosterol-enriched foods: no overall benefit in preventing cardiovascular disease demonstrated | Anses - French Agency for Food, Environmental and Occupational Health & Safety [Internet]. [cited Sept. 25, 2025. Available at: https:\/\/www.anses.fr\/fr\/content\/aliments-enrichis-en-phytosterols-un-benefice-global-sur-la-prevention-des-maladies]."},{"key":"10.1016\/j.ando.2025.102471_bib0190","unstructured":"Red yeast rice dietary supplements: seek advice from a healthcare professional before consumption | ANSES - French Agency for Food, Environmental and Occupational Health & Safety [Internet].[cited Sept. 25, 2025. Available at: https:\/\/www.anses.fr\/fr\/content\/complements-alimentaires-base-de-levure-de-riz-rouge-avant-consommation-prenez-conseil]."},{"issue":"19","key":"10.1016\/j.ando.2025.102471_bib0195","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa020194","article-title":"Effects of the amount and intensity of exercise on plasma lipoproteins","volume":"347","author":"Kraus","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ando.2025.102471_bib0200","first-page":"CD003817","article-title":"Exercise for overweight or obesity","volume":"2006","author":"Shaw","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0205","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ahj.2012.04.014","article-title":"Exercise effects on lipids in persons with varying dietary patterns\u2014does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I","volume":"164","author":"Huffman","year":"2012","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ypmed.2008.10.010","article-title":"Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials","volume":"48","author":"Kelley","year":"2009","journal-title":"Prev Med"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0215","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/bjsports-2023-107221","article-title":"Do the associations of daily steps with mortality and incident cardiovascular disease differ by sedentary time levels? A device-based cohort study","volume":"58","author":"Ahmadi","year":"2024","journal-title":"Br J Sports Med"},{"issue":"7224","key":"10.1016\/j.ando.2025.102471_bib0220","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/bmj.319.7224.1523","article-title":"Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and hemostatic factors","volume":"319","author":"Rimm","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ando.2025.102471_bib0225","doi-asserted-by":"crossref","first-page":"d671","DOI":"10.1136\/bmj.d671","article-title":"Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis","volume":"342","author":"Ronksley","year":"2011","journal-title":"BMJ"},{"issue":"10152","key":"10.1016\/j.ando.2025.102471_bib0230","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(18)31571-X","article-title":"No level of alcohol consumption improves health","volume":"392","author":"Burton","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"6676","key":"10.1016\/j.ando.2025.102471_bib0235","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/bmj.298.6676.784","article-title":"Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data","volume":"298","author":"Craig","year":"1989","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0240","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/euhj.1998.1194","article-title":"Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Artery Study","volume":"20","author":"Price","year":"1999","journal-title":"Heart J"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0245","first-page":"101370","article-title":"Smoking and diabetes interplay: comprehensive review and joint statement","volume":"48","author":"Durlach","year":"2022","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib0250","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.je.2016.12.017","article-title":"Smoking and the risk of type 2 diabetes in Japan: a systematic review and meta-analysis","volume":"27","author":"Akter","year":"2017","journal-title":"J Epidemiol"},{"issue":"9","key":"10.1016\/j.ando.2025.102471_bib0255","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jacc.2018.06.036","article-title":"Prevention and treatment of tobacco use: JACC Health Promotion Series","volume":"72","author":"Kalkhoran","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ando.2025.102471_bib0260","author":"Haute Autorit\u00e9 de"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0265","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0270","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ando.2025.102471_bib0275","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ehjcvp\/pvw006","article-title":"Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, and simvastatin: results from VOYAGER","volume":"2","author":"Karlson","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0280","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"issue":"10","key":"10.1016\/j.ando.2025.102471_bib0285","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","article-title":"Resistance and intolerance to statins","volume":"24","author":"Reiner","year":"2014","journal-title":"Metab Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0290","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database","volume":"51","author":"Barter","year":"2010","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2009.08.651","article-title":"Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (VOYAGER)","volume":"105","author":"Nicholls","year":"2010","journal-title":"Am J Cardiol"},{"issue":"9841","key":"10.1016\/j.ando.2025.102471_bib0300","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet Lond Engl"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0305","first-page":"403","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u00a0\u2013\u00a0the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Drugs Ther"},{"issue":"10059","key":"10.1016\/j.ando.2025.102471_bib0310","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ando.2025.102471_bib0315","doi-asserted-by":"crossref","first-page":"g3743","DOI":"10.1136\/bmj.g3743","article-title":"Non-cardiovascular effects associated with statins","volume":"349","author":"Desai","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ando.2025.102471_bib0320","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/2047487314525531","article-title":"What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice","volume":"21","author":"Finegold","year":"2014","journal-title":"J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.ando.2025.102471_bib0325","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246,955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"25","key":"10.1016\/j.ando.2025.102471_bib0330","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"issue":"10355","key":"10.1016\/j.ando.2025.102471_bib0335","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: individual participant data meta-analysis of large-scale, randomized, double-blind trials","volume":"400","year":"2022","journal-title":"Lancet Lond Engl"},{"issue":"10088","key":"10.1016\/j.ando.2025.102471_bib0340","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/S0140-6736(17)31075-9","article-title":"Adverse events associated with unblinded, but not with blinded, therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Arm (ASCOT-LLA): a randomized double-blind placebo-controlled trial and its non-randomized non-blind extension phase","volume":"389","author":"Gupta","year":"2017","journal-title":"Lancet Lond Engl"},{"issue":"22","key":"10.1016\/j.ando.2025.102471_bib0345","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.102471_bib0350","doi-asserted-by":"crossref","first-page":"n135","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomized, placebo-controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"issue":"8A","key":"10.1016\/j.ando.2025.102471_bib0355","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"issue":"9601","key":"10.1016\/j.ando.2025.102471_bib0360","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0365","first-page":"146","article-title":"Statin-associated rhabdomyolysis: is there a dose-response relationship?","volume":"27","author":"Holbrook","year":"2011","journal-title":"Can J Cardiol"},{"issue":"27","key":"10.1016\/j.ando.2025.102471_bib0370","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: the evidence\u00a0\u2013\u00a0focus on glucose homeostasis, cognitive, renal and hepatic function, stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Heart J"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0375","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2012.09.042","article-title":"Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes","volume":"61","author":"Waters","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ando.2025.102471_bib0380","doi-asserted-by":"crossref","first-page":"e030714","DOI":"10.1161\/JAHA.123.030714","article-title":"Lipid-lowering therapy and risk of hemorrhagic stroke: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"B\u00e9trisey","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0385","doi-asserted-by":"crossref","first-page":"108224","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108224","article-title":"LDL-cholesterol lowering agents (statins and PCSK9 inhibitors) and the risk of intracerebral hemorrhage: a network meta-analysis","volume":"34","author":"Li","year":"2025","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0390","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"30","key":"10.1016\/j.ando.2025.102471_bib0395","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1200\/JCO.2006.06.3560","article-title":"Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials","volume":"24","author":"Bonovas","year":"2006","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ando.2025.102471_bib0400","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2019.09.041","article-title":"Effects of statins on memory, cognition, and brain volume in the elderly","volume":"74","author":"Samaras","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.ando.2025.102471_bib0405","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/j.jacc.2021.04.075","article-title":"Effect of statin therapy on cognitive decline and incident dementia in older adults","volume":"77","author":"Zhou","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ando.2025.102471_bib0410","first-page":"415","article-title":"Ezetimibe therapy: mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0415","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0420","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ando.2025.102471_bib0425","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.amjcard.2008.01.041","article-title":"Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials","volume":"101","author":"Kashani","year":"2008","journal-title":"Am J Cardiol"},{"issue":"25","key":"10.1016\/j.ando.2025.102471_bib0430","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0435","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","article-title":"Clinical aspects of PCSK9","volume":"216","author":"Cariou","year":"2011","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.ando.2025.102471_bib0440","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ando.2025.102471_bib0445","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0450","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC State-of-the-Art Review","volume":"76","author":"Katzmann","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.ando.2025.102471_bib0455","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","article-title":"Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: randomized clinical trial","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.ando.2025.102471_bib0460","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1042\/CS20180040","article-title":"PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate","volume":"132","author":"Croyal","year":"2018","journal-title":"Clin Sci (Lond)"},{"issue":"39","key":"10.1016\/j.ando.2025.102471_bib0465","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/eurheartj\/ehw292","article-title":"No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies","volume":"37","author":"Colhoun","year":"2016","journal-title":"Heart J"},{"issue":"15","key":"10.1016\/j.ando.2025.102471_bib0470","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib0475","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s11883-022-01074-y","article-title":"PCSK9 inhibition and risk of diabetes: should we worry?","volume":"24","author":"Carugo","year":"2022","journal-title":"Atheroscler Rep"},{"key":"10.1016\/j.ando.2025.102471_bib0480","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ando.2025.102471_bib0485","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ando.2025.102471_bib0490","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ando.2025.102471_bib0495","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ando.2025.102471_bib0500","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/eurjpc\/zwae144","article-title":"Current treatments for the management of homozygous familial hypercholesterolaemia: a systematic review and commentary","volume":"31","author":"Gu","year":"2024","journal-title":"J Prev Cardiol"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib0505","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","article-title":"Lomitapide for the treatment of pediatric patients with homozygous familial hypercholesterolemia (APH-19): results from the efficacy phase of an open-label, multicenter, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0510","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/liv.15497","article-title":"Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolemia","volume":"43","author":"Larrey","year":"2023","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.ando.2025.102471_bib0515","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ando.2025.102471_bib0520","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.jacadv.2023.100648","article-title":"The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia","volume":"2","author":"Raal","year":"2023","journal-title":"JACC Adv"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0525","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1592\/phco.27.3.412","article-title":"Fibrates: what have we learned in the past 40 years?","volume":"27","author":"Backes","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0530","first-page":"314","article-title":"Niacin and fibrates in atherogenic dyslipidemia: armacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Therapy"},{"issue":"20","key":"10.1016\/j.ando.2025.102471_bib0535","first-page":"2061","article-title":"Safety considerations with fibrate therapy","volume":"60","author":"Davidson","year":"2012","journal-title":"Am J Cardiol"},{"issue":"20","key":"10.1016\/j.ando.2025.102471_bib0540","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ando.2025.102471_bib0545","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.8439","article-title":"Lipid-modifying therapies and risk of pancreatitis: a meta-analysis","volume":"308","author":"Preiss","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0550","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ando.2025.102471_bib0555","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ando.2025.102471_bib0560","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ando.2025.102471_bib0565","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ando.2025.102471_bib0570","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0575","first-page":"651","article-title":"EPA's pleiotropic mechanisms of action: a narrative review","volume":"133","author":"Nelson","year":"2021","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0580","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (the Multi-center, placebo-controlled, double-blind, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.ando.2025.102471_bib0585","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0590","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0595","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacl.2017.10.012","article-title":"Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: randomized, placebo-controlled trial","volume":"12","author":"Stroes","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0600","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ando.2025.102471_bib0605","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0610","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ando.2025.102471_bib0615","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs. corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH Randomized Clinical Trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.ando.2025.102471_bib0620","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0625","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0630","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0635","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ando.2025.102471_bib0640","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0645","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0650","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.jhep.2024.01.030","article-title":"Primary hypocholesterolemia is associated with an increased risk of hepatic complications in the general population","volume":"80","author":"Wargny","year":"2024","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.ando.2025.102471_bib0655","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.numecd.2024.05.021","article-title":"Time-course atherogenic blood lipid response to statin discontinuation in dyslipidemic adults","volume":"34","author":"Alvarez-Jimenez","year":"2024","journal-title":"Metab Cardiovasc Dis"},{"issue":"6807","key":"10.1016\/j.ando.2025.102471_bib0660","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ"},{"issue":"45","key":"10.1016\/j.ando.2025.102471_bib0665","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.ando.2025.102471_bib0670","doi-asserted-by":"crossref","first-page":"E1811","DOI":"10.1002\/humu.21348","article-title":"Molecular spectrum of autosomal dominant hypercholesterolemia in France","volume":"31","author":"Marduel","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ando.2025.102471_bib0675","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2018.08.010","article-title":"High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: Hypercholesterolemia Registry","volume":"277","author":"B\u00e9liard","year":"2018","journal-title":"Atherosclerosis"},{"issue":"25","key":"10.1016\/j.ando.2025.102471_bib0680","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: treatments and clinical guidance","volume":"44","author":"Cuchel","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0685","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-2002-35403","article-title":"The complex role of triglycerides in cardiovascular disease","volume":"2","author":"Abdel-Maksoud","year":"2002","journal-title":"Vasc Med"},{"issue":"9726","key":"10.1016\/j.ando.2025.102471_bib0690","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: analysis of 101 studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0695","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacl.2022.10.008","article-title":"The relationship of alcohol consumption and HDL metabolism in the Multiethnic Dallas Heart Study","volume":"17","author":"Badia","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"47","key":"10.1016\/j.ando.2025.102471_bib0700","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants:tabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0705","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2015.26","article-title":"Chylomicronaemia\u00a0\u2013\u00a0diagnosis and future therapies","volume":"11","author":"Brahm","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2025.102471_bib0710","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2018.06.814","article-title":"Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): recommendations and proposal of an \u201cFCS score\u201d","volume":"275","author":"Moulin","year":"2018","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ando.2025.102471_bib0715","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"issue":"Suppl C","key":"10.1016\/j.ando.2025.102471_bib0720","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/suw009","article-title":"Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia","volume":"18","author":"Ferrari","year":"2016","journal-title":"Eur Heart J Suppl J Eur Soc Cardiol"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0725","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1210\/clinem\/dgaa838","article-title":"10-year comparative follow-up of familial versus multifactorial chylomicronemia syndromes","volume":"106","author":"Belhassen","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ando.2025.102471_bib0730","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11883-014-0437-x","article-title":"Congenital lipodystrophies and dyslipidemias","volume":"16","author":"Prieur","year":"2014","journal-title":"Atheroscler Rep"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib0735","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1194\/jlr.M600312-JLR200","article-title":"Heritability and genetic loci of fatty liver in familial combined hyperlipidemia","volume":"47","author":"Brouwers","year":"2006","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0740","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/hq0202.104059","article-title":"Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study","volume":"22","author":"Veerkamp","year":"2002","journal-title":"Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.ando.2025.102471_bib0745","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2025.102471_bib0750","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.atherosclerosis.2021.11.032","article-title":"Polygenic architecture and cardiovascular risk of familial combined hyperlipidemia","volume":"340","author":"Trinder","year":"2022","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ando.2025.102471_bib0755","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0022-2275(20)32417-2","article-title":"Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes","volume":"40","author":"Mahley","year":"1999","journal-title":"J Lipid Res"},{"issue":"19","key":"10.1016\/j.ando.2025.102471_bib0760","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1056\/NEJMicm1713658","article-title":"Xanthoma Striatum Palmare","volume":"378","author":"Koehler","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0765","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1210\/clinem\/dgac503","article-title":"Dysbetalipoproteinemia is associated with increased risk of coronary and peripheral vascular disease","volume":"108","author":"Paquette","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.102471_bib0770","article-title":"Evaluation of biochemical algorithms to screen dysbetalipoproteinemia in \u025b2\u025b2 and rare APOE variants carriers","author":"Michenaud","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.1016\/j.ando.2025.102471_bib0775","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/ATVBAHA.118.310990","article-title":"Liraglutide reduces postprandial hyperlipidemia by increasing ApoB48 (Apolipoprotein B48) catabolism and by reducing ApoB48 production in patients with type 2 diabetes mellitus","volume":"38","author":"Verg\u00e8s","year":"2018","journal-title":"Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0780","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/dom.14328","article-title":"Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes","volume":"23","author":"Taskinen","year":"2021","journal-title":"Obes Metab"},{"key":"10.1016\/j.ando.2025.102471_bib0785","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1567-5688(15)30001-5","article-title":"A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: from an expert consensus meeting on the role of fenofibrate-statin combination therapy","volume":"19","author":"Aguiar","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"9","key":"10.1016\/j.ando.2025.102471_bib0790","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1210\/jc.2019-01338","article-title":"Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society* Clinical Practice Guideline","volume":"104","author":"Rosenzweig","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.102471_bib0795","doi-asserted-by":"crossref","first-page":"101196","DOI":"10.1016\/j.plipres.2022.101196","article-title":"Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: meta-analysis of randomized controlled trials","volume":"88","author":"Yang","year":"2022","journal-title":"Prog Lipid Res"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0800","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0805","first-page":"442","article-title":"Cardiovascular disease in type 1 diabetes: review of epidemiological data and underlying mechanisms","volume":"46","author":"Verg\u00e8s","year":"2020","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0810","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0815","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tem.2020.01.015","article-title":"Dyslipidemia in type 1 diabetes: a masked danger","volume":"31","author":"Verg\u00e8s","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"9607","key":"10.1016\/j.ando.2025.102471_bib0820","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet Lond Engl"},{"issue":"21","key":"10.1016\/j.ando.2025.102471_bib0825","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ando.2025.102471_bib0830","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2174\/157016112803520864","article-title":"Mechanisms of diabetic dyslipidemia: atherogenesis","volume":"10","author":"Arca","year":"2012","journal-title":"Vasc Pharmacol"},{"issue":"11","key":"10.1016\/j.ando.2025.102471_bib0835","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/dom.12133","article-title":"Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial","volume":"15","author":"Hermansen","year":"2013","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.ando.2025.102471_bib0840","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc20-1843","article-title":"Liraglutide increases the catabolism of apolipoprotein b100-containing lipoproteins in patients with type 2 diabetes and reduces proprotein convertase subtilisin\/\/type 9 expression","volume":"44","author":"Verg\u00e8s","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2025.102471_bib0845","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ajpc.2024.100679","article-title":"Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: meta-analysis of randomized placebo-controlled trials","volume":"18","author":"Rivera","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"9889","key":"10.1016\/j.ando.2025.102471_bib0850","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet Lond Engl"},{"issue":"9731","key":"10.1016\/j.ando.2025.102471_bib0855","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10.1016\/j.ando.2025.102471_bib0860","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0865","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ando.2025.102471_bib0870","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"issue":"9784","key":"10.1016\/j.ando.2025.102471_bib0875","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (of Heart and Renal Protection): a randomized placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ando.2025.102471_bib0880","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomized trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1016\/j.ando.2025.102471_bib0885","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER Trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"10.1016\/j.ando.2025.102471_bib0890","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tu\u00f1\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0895","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/CIRCULATIONAHA.112.000500","article-title":"Blood pressure and cholesterol control in hypertensive hypercholesterolemic patients: national health and nutrition examination surveys 1988\u20132010","volume":"128","author":"Egan","year":"2013","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.ando.2025.102471_bib0900","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"ESC Cardiovascular risk collaboration","year":"2021","journal-title":"Eur Heart J"},{"issue":"9438","key":"10.1016\/j.ando.2025.102471_bib0905","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib0910","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0915","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.amjcard.2007.08.033","article-title":"Impact of systemic hypertension on the cardiovascular benefits of statin therapy\u00a0\u2013\u00a0a meta-analysis","volume":"101","author":"Messerli","year":"2008","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0920","first-page":"73","article-title":"Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice","volume":"108","author":"Agca","year":"2022","journal-title":"Heart Br Card Soc"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0925","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders","volume":"76","author":"Agca","year":"2017","journal-title":"Rheum Dis"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0930","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumor necrosis factor inhibitors, non-steroidal anti-inflammatory drugs, and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib0935","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","article-title":"Cardiovascular effects of approved drugs for rheumatoid arthritis","volume":"17","author":"Atzeni","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib0940","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/18734251MTAyoOTM05","article-title":"Cardiovascular risk assessment in people living with HIV: a systematic review and meta-analysis of real-life data","volume":"18","author":"Grand","year":"2020","journal-title":"Curr HIV Res"},{"issue":"8","key":"10.1016\/j.ando.2025.102471_bib0945","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib0950","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/23744235.2021.1982140","article-title":"Effectiveness of ezetimibe in human immunodeficiency virus patients treated for hyperlipidemia: a systematic review and meta-analysis","volume":"54","author":"Nirmala","year":"2022","journal-title":"Infect Dis Lond Engl"},{"key":"10.1016\/j.ando.2025.102471_bib0955","unstructured":"EACS Guidelines [Internet]. [cited 2025 Sep 25]. EACS Guidelines 2024. [Available from: https:\/\/eacs.sanfordguide.com\/]."},{"issue":"9976","key":"10.1016\/j.ando.2025.102471_bib0960","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"15","key":"10.1016\/j.ando.2025.102471_bib0965","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ando.2025.102471_bib0970","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ando.2025.102471_bib0975","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ando.2025.102471_bib0980","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ehjcvp\/pvad009","article-title":"LDL lowering effect of PCSK9 inhibition is reduced in women","volume":"9","author":"Myasoedova","year":"2023","journal-title":"Heart J Cardiovasc Pharmacother"},{"issue":"34","key":"10.1016\/j.ando.2025.102471_bib0985","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Heart J"},{"issue":"20","key":"10.1016\/j.ando.2025.102471_bib0990","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.jacc.2020.03.060","article-title":"Summary of updated recommendations for primary prevention of cardiovascular disease in women: review","volume":"75","author":"Cho","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib0995","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0000000000000927","article-title":"Lipid metabolism during pregnancy: consequences for mother and child","volume":"35","author":"Mulder","year":"2024","journal-title":"Opin Lipidol"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib1000","doi-asserted-by":"crossref","first-page":"oeae032","DOI":"10.1093\/ehjopen\/oeae032","article-title":"Dyslipidaemia management in pregnant patients: a 2024 update","volume":"4","author":"Lewek","year":"2024","journal-title":"Eur Heart J Open"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib1005","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1210\/clinem\/dgaf409","article-title":"Course of pregnancies and occurrence of acute pancreatitis in women with chylomicronemia","volume":"111","author":"Larouche","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2025.102471_bib1010","doi-asserted-by":"crossref","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: cohort study","volume":"350","author":"Bateman","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ando.2025.102471_bib1015","doi-asserted-by":"crossref","first-page":"1076372","DOI":"10.3389\/fmed.2022.1076372","article-title":"Pravastatin in preeclampsia: meta-analysis and systematic review","volume":"9","author":"M\u00e9sz\u00e1ros","year":"2022","journal-title":"Front Med"},{"issue":"10\u201311","key":"10.1016\/j.ando.2025.102471_bib1020","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0039-128X(00)00174-4","article-title":"Progestins and cardiovascular risk markers","volume":"65","author":"Sitruk-Ware","year":"2000","journal-title":"Steroids"},{"issue":"24","key":"10.1016\/j.ando.2025.102471_bib1025","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"Lidegaard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2025.102471_bib1030","first-page":"e082801","article-title":"Stroke and myocardial infarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study","volume":"388","author":"L\u00f8kkegaard","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ando.2025.102471_bib1035","volume":"[146","year":"2011"},{"key":"10.1016\/j.ando.2025.102471_bib1040","unstructured":"Haute Autorit\u00e9 de sant\u00e9 [Internet]. Contraception in women at cardiovascular risk.[cited Sept. 29, 2025. Available at: https:\/\/www.has-sante.fr\/jcms\/c_1638478\/fr\/contraception-chez-la-femme-a-risque-cardiovasculaire]."},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib1045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41569-023-00926-7","article-title":"The menopausal transition period and cardiovascular risk","volume":"21","author":"Mehta","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib1050","first-page":"CD002229","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","volume":"2015","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"10.1016\/j.ando.2025.102471_bib1055","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1161\/CIR.0000000000000912","article-title":"Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association","volume":"142","author":"El Khoudary","year":"2020","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ando.2025.102471_bib1060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.122.061559","article-title":"Rethinking menopausal hormone therapy: whom, what, why, and how long?","volume":"147","author":"Cho","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib1065","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1186\/s12877-020-01801-7","article-title":"A scoping review of the Clinical Frailty Scale","volume":"20","author":"Church","year":"2020","journal-title":"BMC Geriatr"},{"issue":"10263","key":"10.1016\/j.ando.2025.102471_bib1070","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(20)32233-9","article-title":"Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 40-70-100: a contemporary primary prevention cohort","volume":"396","author":"Mortensen","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"22","key":"10.1016\/j.ando.2025.102471_bib1075","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.jacc.2013.07.069","article-title":"Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis","volume":"62","author":"Savarese","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.ando.2025.102471_bib1080","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.117.028271","article-title":"Primary prevention with statin therapy in the elderly: from the contemporary JUPITER and HOPE-3 Randomized Trials","volume":"135","author":"Ridker","year":"2017","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib1085","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/CIRCULATIONAHA.118.039415","article-title":"Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): randomized trial","volume":"140","author":"Ouchi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ando.2025.102471_bib1090","doi-asserted-by":"crossref","first-page":"k3359","DOI":"10.1136\/bmj.k3359","article-title":"Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study","volume":"362","author":"Ramos","year":"2018","journal-title":"BMJ"},{"issue":"10170","key":"10.1016\/j.ando.2025.102471_bib1095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"10263","key":"10.1016\/j.ando.2025.102471_bib1100","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomized controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"43","key":"10.1016\/j.ando.2025.102471_bib1105","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1093\/eurheartj\/ehz458","article-title":"Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France","volume":"40","author":"Giral","year":"2019","journal-title":"Eur Heart J"},{"issue":"10263","key":"10.1016\/j.ando.2025.102471_bib1110","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomized controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib1115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2020.6084","article-title":"Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: meta-analysis","volume":"181","author":"Yourman","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"7","key":"10.1016\/j.ando.2025.102471_bib1120","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: Mendelian Randomization Analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"39","key":"10.1016\/j.ando.2025.102471_bib1125","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Heart J"},{"issue":"12","key":"10.1016\/j.ando.2025.102471_bib1130","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.acvd.2021.10.009","article-title":"Lipoprotein(a): pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Soci\u00e9t\u00e9 Francophone d\u2019Ath\u00e9roscl\u00e9rose (NSFA)","volume":"114","author":"Durlach","year":"2021","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.ando.2025.102471_bib1135","doi-asserted-by":"crossref","first-page":"100885","DOI":"10.1016\/j.ajpc.2024.100885","article-title":"Lipoprotein(a) throughout life in women","volume":"20","author":"Corral","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.ando.2025.102471_bib1140","doi-asserted-by":"crossref","first-page":"119218","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The Brussels International Declaration on lipoprotein(a) testing and management","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"},{"issue":"10155","key":"10.1016\/j.ando.2025.102471_bib1145","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet Lond Engl"},{"issue":"13","key":"10.1016\/j.ando.2025.102471_bib1150","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib1155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin-\/9, on lipoprotein(a) concentrations (a pooled analysis of 150\u00a0mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib1160","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ando.2025.102471_bib1165","first-page":"753","article-title":"Lp(a)-lowering agents in development: era in tackling the burden of cardiovascular risk?","volume":"18","author":"Katsiki","year":"2025","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.ando.2025.102471_bib1170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib1175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pcad.2016.08.006","article-title":"Diagnosis and treatment of high density lipoprotein deficiency","volume":"59","author":"Schaefer","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.ando.2025.102471_bib1180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MOL.0b013e32803dbdd6","article-title":"Genetic factors affecting HDL levels, structure, metabolism, and function","volume":"18","author":"Sviridov","year":"2007","journal-title":"Opin Lipidol"},{"key":"10.1016\/j.ando.2025.102471_bib1185","unstructured":"2021_06_scientific_argument_genetic_intestinal_hypocholesterolemia_vf.pdf [Internet]. [cited 2025 Sep 29. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-06\/2021_06_argumentaire_scientifique_hypocholesterolemie_intestinale_genetique_vf.pdf]."},{"issue":"3","key":"10.1016\/j.ando.2025.102471_bib1190","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamacardio.2022.5271","article-title":"Association of rare protein-truncating DNA variants in APOB or PCSK9 with low-density lipoprotein cholesterol level and risk of coronary heart disease","volume":"8","author":"Dron","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.ando.2025.102471_bib1195","first-page":"166","article-title":"Prevalence of liver steatosis and fibrosis in adults with primary hypobetaliproteinemia: results from the HYPOCHOL Study","volume":"23","author":"Smati","year":"2025","journal-title":"Gastroenterol Hepatol"},{"issue":"38","key":"10.1016\/j.ando.2025.102471_bib1200","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625007905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426625007905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:51:50Z","timestamp":1773283910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426625007905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":240,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0003426625007905"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2025.102471","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of dyslipidemia in adults. A consensus statement from the French Society of Endocrinology (SFE), the French-speaking Diabetes Society (SFD), the New French-speaking Society of Atherosclerosis (NSFA) and the French Society of Cardiology (SFC)","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2025.102471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102471"}}